WISHESIf you're wishing for a White Christmas, well, depending where you are, you may get your wish and be very pleased. If your wish was for 2018 to be a great year for your investment in SVA, well, I'm as disappointed as you are. We are simply running out of days and I wouldn't expect any news of significance this close to the Holidays and the end of the year. We'll have to carry on our hopes that this company can pull it together in 2019. As I've stated before, we need to hear news that involves $$$ sooner than later. Maybe something like the company has been talking about for what it seems like forever. A licencing agreement, a collaboration with large pharma, a partmerdhip, or whatever. This company will need more money to operate very shortly, as I see a high burn rate with all this hiring of IR firms, travel expenses, maintaining London facility, etc,etc. And as much as the report on Hemo advancements was very encouracing, $$$ will be required to move that forward. And if the 2020 Project had granted any more funds, then I'm sure we would have heard about it. So if the next news is that the Chicago trial has finally started, don't expect a surge in share price. It was supposed to start long ago and is now expected. I DO wish the best for this company in the near future as I am a sharteholder, but whatever it is that is holding up the start of FDA approved trials had better get straightened out soon or maybe FDA will sense something not going quite right and revisit their approval. I'm sure they must have some sort of time frame as to when a trial has to commence after gaining approval. Or maybe I'm wrong. Share your thoughts.